What Is Melanotan I?

1. How Melanotan I changes skin pigment

Your body produces alpha-melanocyte-stimulating hormone, usually shortened to α-MSH. Melanotan I is a modified version of this hormone. It activates melanocortin receptors, with predominant binding to MC1R, according to the afamelanotide prescribing information.

MC1R signaling stimulates pigment-producing cells called melanocytes. Afamelanotide increases eumelanin, the brown-black form of melanin, independently of sunlight or artificial UV. It changes pigment production within the skin; applying a surface tanning product is a different process.

Researchers tested the pigment itself. In Dorr and colleagues’ 2000 study, seven volunteers with Fitzpatrick skin types III or IV received MT1 over two weeks. These participants already had skin capable of tanning. Forearm biopsies taken a week after treatment ended showed a mean 98% increase in a chemical marker of eumelanin. Forehead samples from three participants showed a 49% increase.

Those percentages describe laboratory measurements in small tissue samples. They do not mean someone became “98% darker,” doubled their sun protection or cut their cancer risk in half. The investigators detected tanning at three of eight measured body sites, so the result also cannot promise an even whole-body tan.

2. What the human studies show

The research spans cosmetic pigmentation experiments and treatment of erythropoietic protoporphyria, or EPP. EPP causes severe pain after light exposure because a light-reactive substance called protoporphyrin accumulates in the body. Its symptoms and treatment outcomes differ from ordinary sunburn.

How much did light tolerance improve?

In the 2015 trials, the US group recorded median total pain-free direct sunlight exposure of 69.4 hours with afamelanotide versus 40.8 hours with placebo over six months. The difference between those medians is 28.6 hours across the study, not per day or per implant.

The European trial reported 6.0 versus 0.8 hours over nine months. Its primary endpoint counted exposure between 10 a.m. and 3 p.m.; the US window extended to 6 p.m. Different definitions and observation periods prevent a direct comparison of the totals. The European trial also recorded 77 phototoxic reactions with afamelanotide versus 146 with placebo.

The trials support improved light tolerance in EPP. They do not measure how long a healthy user can sunbathe without DNA damage. Clinuvel, the developer, helped fund the research; these were trials within a drug-development program.

3. Tanning results, onset and sun protection

The 2000 study measured pigmentation at day 14 and day 21. Those scheduled assessments tell us when researchers documented a change, rather than the first day every participant noticed one. They cannot establish a standard “results in seven days” claim for retail MT1.

In the 2004 paper, one eight-person experiment compared sunlight alone with sunlight plus MT1. Enhanced pigmentation in the MT1 group persisted at least three weeks longer than in the sunlight-only controls. Another experiment found 47% fewer sunburn cells at a UV-exposed neck site in the treated participants who tanned.

A sunburn cell is a laboratory sign of cell injury. Fewer such cells in a small experiment is an interesting photoprotection result, but cannot establish a sunscreen-equivalent SPF, prevention of melanoma or a safe tanning-bed schedule. These trials did not follow enough people for enough years to answer those questions.

The TGA warns that pigmentation from melanotan does not provide the protection of suitable sunscreen. Keep sunscreen, clothing and shade in the picture. Increasing UV exposure because a tan looks darker can undermine the original goal of reducing UV damage.

4. Melanotan I vs Melanotan II

The Roman numerals identify different peptides, not two strengths of one product.

The Melanotan II guide covers its broader melanocortin activity, erectile effects and adverse-event reports. Those findings cannot be assigned to MT1 merely because both compounds can darken skin.

Calling MT1 “the safer tanning peptide” goes beyond the evidence. Afamelanotide has a more developed clinical record, but a comparison between monitored patients receiving a manufactured implant and people buying unverified MT2 is confounded by product quality, patient selection and medical supervision.

PT-141, or bremelanotide, is another related molecule with its own sexual-desire trials. Neither its results nor MT2’s appetite effects establish that MT1 raises testosterone, enhances libido or causes sustained fat loss.

5. Scenesse, MT1 injections and nasal sprays

The FDA approved Scenesse on October 8, 2019, for adults with a history of phototoxic reactions from EPP. That approval applies to a defined medicine and indication. It does not approve cosmetic MT1 products.

The implant releases afamelanotide from a manufactured delivery system. A vial of powder dissolved for injection has a different release profile, and a nasal spray introduces another absorption route. Equal labeled milligrams do not establish equal blood concentrations or duration of exposure. Bioavailability depends on how a formulation delivers the molecule.

The studies above do not establish effectiveness or systemic safety for retail MT1 nasal sprays. Avoiding a needle removes needle-related risks; it does not verify identity, strength or absorption. A purity certificate also needs to be read for what was tested. Chemical purity, amount per vial, sterility and clinical effectiveness are separate questions.

The TGA’s tanning-product warning specifically includes products labeled Melanotan I and II. It warns that unapproved products may contain poor-quality or counterfeit ingredients. An ingredient name shared with an approved medicine cannot resolve that uncertainty.

6. Side effects and longer-term safety

The Scenesse label reports the following pooled six-month results in EPP patients:

These rates describe the studied implant, not research injections. Serious allergic reactions, including anaphylaxis, have been reported after approval. Their frequency is unknown. The label recommends full-body skin examinations twice yearly because existing moles and freckles can darken.

In Biolcati and colleagues’ longer follow-up, 115 patients contributed 314 patient-years of observation. The authors reported mostly mild treatment-related adverse effects and sustained improvement in quality of life. “Up to eight years” was the maximum follow-up; it does not mean all 115 patients received eight years of treatment.

That experience provides more information about repeated medical use than a short tanning pilot. It remains too small to exclude rare harms, and the results concern people treated at specialist porphyria centers. They cannot establish the safety of repeated cosmetic cycles with different preparations.

A 2025 German registry report by Homey and colleagues adds observations from 200 treated patients. Quality of life improved from baseline, and 91% continued treatment. The investigators reported a safety profile consistent with earlier trials. There was no untreated comparison group, and the authors disclosed manufacturer research support or employment. Continuing treatment suggests patients found it worthwhile; it is not a 91% efficacy or safety rate.

7. Melanotan I, moles and melanoma

The evidence does not establish that MT1 causes melanoma. It also does not establish that repeated cosmetic use prevents cancer or carries no cancer risk. Pigment production, visible mole changes and malignant growth are different outcomes.

The long-term implant study reported two new moles; one was removed and showed no malignancy. That observation is limited evidence about a monitored group, not a cancer-prevention result. The Scenesse label states that carcinogenicity studies have not been conducted.

A mole that darkens after a pigment-stimulating drug still needs to be assessed on its own features. Do not assume a new, changing or bleeding lesion is an expected tanning response. Arrange a clinician or dermatologist review and include the product and exposure history. Trouble breathing, facial or throat swelling, or faintness after a product requires emergency care.

8. Dosage, half-life and what to record

For its approved indication, Scenesse is a 16 mg implant administered by a trained healthcare professional every two months. The label reports an apparent half-life of approximately 15 hours for that controlled-release implant. That is formulation-specific, not a validated clearance estimate for retail MT1 injections or sprays.

Dividing 16 mg by the days between implants would produce an arithmetic average, not a clinically tested daily dose. The implant’s release, blood clearance and persistence of skin pigment follow different timelines. A half-life model cannot turn one of those measurements into the others.

No approved cosmetic loading phase, maintenance cycle or nasal conversion follows from these studies. Likewise, photographs taken under changing lighting, camera exposure or UV conditions cannot isolate a drug effect.

For a medical discussion about prior use, keep the product label, batch details, route and exposure dates. Record other compounds, UV exposure, symptoms and dated skin photographs alongside them. If the contents were not independently verified, describe the amount as the labeled amount in your peptide log.

9. Melanotan I FAQ

• Is Melanotan 1 the same as Melanotan I or afamelanotide?

  Melanotan 1, Melanotan I and MT1 refer to the peptide developed as afamelanotide. Scenesse is a specific prescription implant containing afamelanotide; an online MT1 label does not establish equivalent contents or delivery.

• Does Melanotan I work without sun exposure?

  Afamelanotide can stimulate pigment production without UV exposure. That does not establish a predictable cosmetic result from a retail MT1 product or make additional sun exposure safe.

• How long does Melanotan I take to work?

  A small 2000 study measured tanning at selected body sites at day 14 and day 21. Those assessment dates do not establish the earliest onset, a universal timeline or how long a tan will last.

• Is Melanotan I safer than Melanotan II?

  Approved afamelanotide has a larger clinical evidence base, but reliable head-to-head trials have not established a safety ranking for recreational MT1 versus MT2. Formulation, exposure and product quality also affect risk.

• Is Melanotan I FDA-approved for tanning?

  No. FDA approved Scenesse for a specific EPP indication in adults in 2019. Cosmetic tanning products sold as Melanotan I do not share that approval.

• Does Melanotan I cause melanoma?

  The available evidence does not establish that MT1 causes melanoma or that repeated cosmetic use is cancer-safe. Mole changes deserve assessment; a tan or a benign-looking photograph cannot rule out skin cancer.

• What is a safe Melanotan I dose or cycle?

  There is no approved cosmetic MT1 dose, loading phase or maintenance cycle. The prescription implant schedule cannot be converted into a self-injection or nasal-spray regimen by dividing its milligrams.

• Does Melanotan I increase libido or burn fat?

  The human studies discussed here measured pigmentation and EPP outcomes. They do not establish MT1 as a libido, testosterone or fat-loss treatment. Results from Melanotan II or PT-141 concern different molecules.

10. Sources